Regeneron falls after appeals court ruling in Eylea case (update)
Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).
Jim Cramer On Regeneron Pharmaceuticals Inc. (REGN) – “I Want You to Own It”
We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...
Regeneron down 3% after appeals court decision in Amgen patent fight
EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...
Appeals court upholds denial of Regeneron motion for injunction against Amgen
Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...